arrow
F

Fabio Salomone

fondazione telethon
H指数:7
被引数:161

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis

免疫疗法在晚期非小细胞肺癌III期试验中,ORR与PFS与OS结局的相关性:系统评价与Meta分析

2025-12-160
OAAI
Quality of Life results and survival outcomes in trials of immunotherapy in advanced cancers: a systematic review and meta-research study

生活质量结果和生存结局在晚期癌症免疫疗法试验中的研究:一项系统评价和元研究

2025-09-180
OAAI
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis

铂类化疗和CTLA-4抑制对非小细胞肺癌中一线抗PD-1/PD-L1药物获得性耐药的影响:一项系统综述和重构的个体患者数据分析

2025-09-020
PREAI
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis

新辅助与围手术期化免疫疗法根据病理反应在可切除非小细胞肺癌中的比较:一项重构的个体患者数据meta分析

2025-06-011
PRE
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
2023-12-0110
PRE